Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma—Results From a Tertiary Cancer Center in India

[1]  A. Sella,et al.  The Evolution of Nephrectomy and Patient Characteristics in Metastatic Renal Cell Carcinoma Patients Enrolled Into First-Line Tyrosine Kinase Inhibitors Clinical Trials. , 2016, Clinical genitourinary cancer.

[2]  P. Shao,et al.  The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma , 2016, Scientific Reports.

[3]  P. Kantoff,et al.  Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[4]  L. Pickering,et al.  Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Kumaraswamy,et al.  Concurrent Chemoradiation for Cancer of the Cervix: Results of a Multi-Institutional Study From the Setting of a Developing Country (India) , 2015, Journal of global oncology.

[6]  C. Porta,et al.  Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma , 2015, British Journal of Cancer.

[7]  M. Fishman,et al.  A Systematic Review of the Efficacy and Safety Experience Reported for Sorafenib in Advanced Renal Cell Carcinoma (RCC) in the Post-Approval Setting , 2015, PloS one.

[8]  T. Choueiri,et al.  The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. , 2015, The Lancet. Oncology.

[9]  R. Kapoor,et al.  Renal cell carcinoma in India demonstrates early age of onset & a late stage of presentation , 2014, The Indian journal of medical research.

[10]  Kenya Yamaguchi,et al.  Sunitinib versus sorafenib as first-line therapy for patients with metastatic renal cell carcinoma with favorable or intermediate MSKCC risk factors: A multicenter randomized trial, CROSS-J-RCC. , 2014 .

[11]  G. Hermann,et al.  Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer Group (DARENCA) study-2. , 2014, European journal of cancer.

[12]  Kumar Gaurav,et al.  Emerging risk factors for cardiovascular diseases: Indian context , 2013, Indian journal of endocrinology and metabolism.

[13]  J. Reeves,et al.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.

[14]  K. Prabhash,et al.  Sunitinib in metastatic renal cell carcimoma: a single-center experience. , 2013, Indian journal of cancer.

[15]  U. Harmenberg,et al.  Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000–2008) , 2013, British Journal of Cancer.

[16]  T. Choueiri,et al.  External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. , 2013, The Lancet. Oncology.

[17]  P. Lara,et al.  Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients. , 2012, Clinical genitourinary cancer.

[18]  Choung-Soo Kim,et al.  Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features , 2012, Journal of Cancer Research and Clinical Oncology.

[19]  C. Bokemeyer,et al.  Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  J. Hajdenberg,et al.  Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America , 2010, Cancer.

[21]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Okada,et al.  [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[23]  D. Cella,et al.  Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[25]  C. Porta,et al.  Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  D. Pal,et al.  Clinical characteristics of renal cell carcinoma: Five years review from a tertiary hospital in Eastern India. , 2016, Indian journal of cancer.

[27]  T. Choueiri,et al.  Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  M. Gordon Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma , 2008 .